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The purpose of this study is to determine if patients with chronic patellar tendinopathy will improve clinically after the inoculation
of bone marrow mononuclear cells (BM-MNCs). Eight patients with chronic patellar tendinopathy were included. Patients
averaged 24 years old (range 14–35). All patients were refractory to conservative treatment for at least 6 months before the
procedure. BM-MNCs were harvested from the iliac bone crest and inoculated under ultrasound guide in the patellar tendon
lesion. Improvement was assessed through established clinical scores and ultrasound. At 5-year followup, statistically signiﬁcant
improvement was seen for most clinical scores. Seven of eight patients said they would have the procedure again if they had the
same problem in the opposite knee and were completely satisﬁed with the procedure. Seven of 8 patients thought that the results
of the procedure were excellent. According to our results, inoculation of BM-MNCs could be considered as a potential therapy for
those patients with chronic patellar tendinopathy refractory to nonoperative treatments.
1.Introduction
Chronic patellar tendinopathy is a common and disable
disease.Despiteimprovementsinearlydetection,evaluation,
and advance rehabilitation techniques, treatment is long and
tedious. Multiple approaches, both surgical and nonsurgical,
have been suggested.
The precise mechanism by which tendinopathy develops
in humans is not quite understood. Histopathology studies
have consistently shown that tendinopathy in humans is
typically due to tendinosis [1]. Tendinosis is characterized
histologically by tissue degeneration with failed reparative
responseandabsenceofinﬂammatorycells.Thepathological
region is distinct from normal tendon with both matrix
and cellular changes. Instead of clearly deﬁned, parallel,
and slightly wavy collagen bundles, tendinosis is associated
with relative expansion of the tendinous tissue, loss of the
longitudinalalignmentofcollagenﬁbers,andlossoftheclear
demarcation between adjacent collagen bundles. Multiple
cellular changes coexist with these matrix changes. The most
obvious is hypercellularity resulting from an increase in cel-
lular proliferation. There is atypical ﬁbroblast and endothe-
lial cellular proliferation and extensive neovascularization.
It has been suggested that ﬁbroblast in tendinosis had an
abnormal respond to healing stimulus, probably due to cell
transformation [2]. Increased expression of MMP has also
been shown in diseased tendons [3].
Recent work in vitro has focused on the use of bone
marrow mononuclear stem cells (BM-MNCs) combined
with growth factors to improve the quality and speed of
healing in tendinosis repair. Clinically, PRP or platelet-rich
plasma has shown to improve pain and function over time in
patients with chronic patellar tendinopathy [4–6].
BM-MNCs are pluripotential cells and are believed to
play an important role in connective tissue repair such as
tendon, ligament, bone, and cartilage. Several animal studies
have shown that the inoculation of these cells can accelerate
tendon healing [7–9]. A combination of BM-MNCs and
anabolic growth factors would seem an attractive approach
for improving connective tissue repair.2 Stem Cells International
Table 1: Sonographic grading of the patellar tendinopathy. Grade
ratio between injured area and whole tendon section at US scan.
Grade
1 Injured area is less than 20% of the whole tendon section
2 Injured area is between 20% and 50% of the whole tendon
section
3 Injured area is more than 50% of the whole tendon section
4 Subtotal or total tear, respectively, with partial and total
tendon retraction
The objective of this study is to evaluate the outcomes of
inoculation of BM-MNCs in patients with chronic patellar
tendinopathy of the knee through established outcomes
scales, clinical assessment followup, and ultrasound images.
2.MaterialsandMethods
2.1. Patient Selection. Between June 2005 and September
2006, 8consecutivepatientswithchronicpatellartendinopa-
thy treated with mononuclear BM-MNCs were included.
Approval for the study was obtained by the institutional
review board at our institution, and all patients signed
informed consent to participate. Indications for BM-MNCs
were history of pain (more than 6 months), tenderness
on patellar tendon palpation, and imaging ﬁndings of
degenerative changes (MRI). All patients had failed previous
nonoperative treatment for at least six months including all
or a combination of conventional stretching exercises and
strengthening, and were classiﬁed as grade III-B according
to the criteria originally described by Blanzina and later
modiﬁed by Warden et al. [10] (patients unable to par-
ticipate in sports at the same level as before the onset
of symptoms). Exclusion criteria were systemic disorders
such as diabetes, rheumatoid arthritis, coagulopathies, car-
diovasculardiseases,infections,immunodepression,patients
in therapy with anticoagulants, and use of NSAIDs in the
ﬁve days before bone marrow aspiration. All patients had
an ultrasound (US) done before surgery and at 6 months
postoperatively. Based on US ﬁndings, four grades of patellar
tendinopathy were identiﬁed (Table 1)[ 11].
2.2. Bone Marrow Aspiration. Under general anesthesia,
bone marrow was aspirated from anterior iliac crest using a
bone marrow harvest needle (Medical Device Technologies,
Inc., Gainesville, Fla, USA) with 20-mL syringes preﬁlled
with anticoagulant citrate dextrose (1.5mL) to prevent
blood clotting. Ficoll-Paque Premium (3mL) was added to
centrifugetubes.Thenthebonemarrowwascarefullylayered
in the Ficoll-Paque Premium, making sure that the bone
marrow sample did not mix with the Ficoll-Paque Premium.
Then centrifugation was done, and the upper layer contain-
ing plasma and platelets using sterile pipette was drawn oﬀ
leaving the mononuclear cells undisturbed at the interface.
The layer of mononuclear cells was transferred to a sterile
centrifuge tube. These cells were washed by centrifugation.
Supernant was removed and the mononuclear cells were
∗
Figure 1: Preoperative magnetic resonance imaging showing
hypodens area in the proximal aspect of the patellar tendon (∗).
resuspend in 6 to 8mL balanced solution appropriate for
application.
2.3. Haematological Analysis. Haematological analysis was
performed according to a previously published method [12].
The numbers of nucleated cells in BMA (bone marrow aspi-
ration) were determined before and after concentration with
anautomatedhaematologyanalyzer.Theconcentrationratio
was determined as follows: concentration ratio = number
of nucleated cells in BMA after concentration/number of
nucleated cells in BMA before concentration.
2.4. Inoculation. The area of injury was identiﬁed, and the
zone was clearly marked based on physical examination,
imaging studies, and area of maximal tenderness. An
ultrasound-guided injection was used to better identify the
pathologic area. (Figures 1, 2,a n d3). After the injection,
the patients were sent home with instructions to limit the
use of the leg for at least 24hs and use cold therapy for
pain. Then, patients started with stretching exercises and
mild activities (such as bicycle exercises and mild exercised
in the pool). After a month, patients were allowed to do
recreational sports or activities as tolerated.
2.5.OutcomesAssessment. Onlypatients witha minimum 24
months followup were included for analysis. Questionnaires
were administered preoperatively, 1 year postoperatively and
then annually. Subjective measures were based on several
scoring systems including Lysholm, Tegner, Cincinnati,
international knee documentation committee (IKDC), knee
injury ad osteoarthritis outcome score (KOOS) and Short
Form-12 (SF12) [13–15] .T h eK O O Sh o l d s5s e p a r a t e l y
scored subscales: pain, other disease-speciﬁc symptoms,
activities of daily living (ADL) function, sport and recreation
function, and knee-related quality of life (QOL) [12].
Patients were also asked to rate the overall condition of
their knee at the time of the last followup: 0 to 2 poor
(signiﬁcant limitations that aﬀect activities of daily living);
3 to 4, fair (moderate limitations that aﬀect activities of
daily living, no sport possible); 5 to 6, good (some limitationStem Cells International 3
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Figure 2: Preoperative US (ultrasound) of the patellar tendon
showing areas of edema (hypoechoic) (∗∗). RT: rotulian or patellar
tendon.
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Figure 3: Under US guide, the cells were inoculated. Observe the
hypoechoic area (∗) where the cells were inoculated. An acustic
shadowisevidentaftertheinoculationofthecells(∗∗).RT:rotulian
or patellar tendon.
with sports but I can participate, I compensate); 7 to 8, very
good (rare limitations, able to participate); 9 to 10, excellent
(abletodowhateverIwishnoproblems).Patientsatisfaction
with the procedure was elicited with the following scale:
completelysatisﬁed,mostlysatisﬁed,somewhatsatisﬁed,and
unsatisﬁed. Finally, the patients were asked if, based on their
experience, they had the same problem in the opposite knee,
would they have the same surgery again.
An ultrasound was performed in all patients prior to
inoculation and at 6 months after the injection to objectively
evaluate tendon healing.
2.6. Statistical Analysis. Descriptive statistics were calcu-
lated according to standard methods, including frequencies,
means, standard deviations, and ranges when appropriate.
Clinical outcome scores were analyzed at 2 time points:
Table 2: Outcome score changes from preoperative results to ﬁnal
results, with P value for all outcome scales.
Knee scoring system Preoperative Postoperative P value
Tegner 2 8 0.0061
Lysholm 33 53 0.1043
IKDC 36 69 0.047
KOOS
Pain 47 63 0.2399
Symptoms 44 71 0.0086
ADL 63 90 0.0246
Sport 24 63 0.0078
QOL 50 71 0.0825
SF-12
Mental 52 57 0.5589
Physical 41 44 0.438
IKDC: international knee documentation Committee; KOOS: knee injury
and osteoarthritis outcome score; ADL: activities of daily living; QOL:
quality of life; SF-12: short form-12.
preoperatively and at the most recent followup. Score
improvementwascalculatedusingapairedttest.Astatistical
signiﬁcance was set at P<0.05. Statistics were performed
usingGraphPadsoftware(GraphPadSoftware,LaJolla,Calif,
USA).
3. Results
The mean age of the patients was 24 (range 14–35). Four
patients were female and four male. No complications were
recorded. The average total number of cells inoculated
injected was 30 × 103. The average patient followup was 5
years (range, 3–6). Overall, statistically signiﬁcant improve-
ment (preoperative to postoperative) for the Tegner (2 to
8, P = 0.006), IKDC scores (36 to 69, P = 0.047), KOOS
symptoms (44 to 71 P = 0.0086), KOOS ADL (63 to 90,
P = 0.0086), KOOS sport (24 to 63 P = 0.0078). No
statistical improvement was seen for the Lysholm (33 to 53
P = 0.1043), KOOS pain (47 to 63 P = 0.2399), KOOS QOL
(50 to 71 P = 0.0825), SF-12 mental (52 to 57 P = 0.5589)
and SF-12 physical (41 to 44 P = 0.438). Detailed overall
resultsareshowninTable 2.Consideringeachtimefollowup,
there was signiﬁcant improvement at 2 years and plateau till
last follow-up at 5 years (Figure 4).
Seven of eight patients said they would have the proce-
dure again if they had the same problem in the opposite
knee. Seven of eight patients were completely satisﬁed with
the procedure, one patient was somewhat satisﬁed. Seven
of 8 patients thought that the results of the procedure were
excellent (10, scale from 0–10). None of the patients had
additional procedures.
3.1.CellsInoculated. Thenumberofnucleatedcellsobtained
from bone marrow aspiration was 37 × 103 cells (±10). After
concentration (cell recovery 85%) the average total numbers
o fB M - M N C sw e r e4 5× 103 (±5).4 Stem Cells International
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Figure 4: Preop. and yearly time follow-up for IKDC, Lysholm,
KOOS pain and symptoms.
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Figure 5
3.2. Ultrasound Evaluation. All patients were grade 2-3
before inoculation. At 6 months 8 of the nine patients had
grade 1. Only one patient had grade 3 (Figure 5).
4. Discussion
In this study, 8 patients with chronic patellar tendinopathy
were treated with autologous BM-MNCs. We compared
the outcomes of patients before and at 5 years after the
inoculation, showing statistical improvement in most of the
outcomes scores at the time of followup. Patients reached
a plateau after one year followup. Although this can be
argued as may be a self-limiting process, none of our patients
had a recurrence which is normally reported to be between
12 to 27% in patients treated nonoperatively [9]
The major limitation of this study is the lack of control
group, resulting in a low level of evidence study (Level 4)
andthe fewnumberof patients that wereincluded. Although
we did not compare MRI pre- and postoperative to assess
healing, we used ultrasound to assess healing before and at
last followup. Warden et al. compared the accuracy between
MRI and US in conﬁrming clinical diagnosis of patellar
tendinopathy. They suggested that US is more accurate than
MRI conﬁrming clinical diagnosed patellar tendinopathy
(83% versus 70% resp.) [10]. To our knowledge, there have
not been published articles that assess the eﬀect of BM-
MNCs for the treatment of patellar chronic tendinopathy in
patients.
Treatmentofchronicpatellartendinopathyischallenging
secondary to the low capacity of healing that the tendon
has resulting in long and tedious treatments. Identifying
alternative strategies is a priority. The tendon itself is
relatively cell poor, with a low turnover rate. Recently, it
has been proposed that adult stem cells would be good
candidates for cell-based tendon regeneration [9, 16]. The
exact role of implanted stem cells on tendon healing remains
uncertain. One possibility is that they become diﬀerentiated
into tenocytes within the healing tendon environment and
participate in healing through collagen production and
remodeling. Alternatively, it has been suggested that BM-
MNCsmaycontributetohealingbyactingas“growthfactors
pumps” rather than through terminal diﬀerentiation [11–
17].
Chongetal.studiedin57rabbitstheeﬀectofinoculation
of BM-MNCs in an Achilles tendon injury model. A
transection in the Achilles tendon was performed and either
treated with Kessler suture with or without the addition of
MSCs. Histological, immunohistochemistry, morphometric,
and mechanical testing was performed. The BM-MNCs
improved mechanical and histological parameters only at
early stages (3 weeks), suggesting the eﬀect on accelerating
healing at early time period [8]. Multiple questions still
remain uncertain. Time is crucial for biological therapies.
It is not clear at what time point the inoculation should be
considered and the number of applications needed. Should
be wait for 6 months of nonresponding medical treatment or
try this therapy earlier? Should be inoculate these cells alone
or combine them with growth factors such as PRP? Shall we
give only one injection or try serial inoculations? In all our
patients, we did one inoculation of BM-MSC after 6 months
offailednonoperativetreatment.However,intheonepatient
that did not improve, probably a second inoculation of BM-
MNCs or inoculation of PRP would may have been the
answer.
We believe that this therapy could be considered as
an alternative treatment for those patients who have failed
nonoperative treatment before surgical intervention is con-
sidered. Further control studies will be needed to determine
if inoculation of BM-MNCs can improve tendon healing in
patients with chronic patellar tendinopathy. According toStem Cells International 5
this study, inoculation of BM-MNCs for the treatment of
patellar tendinopathy is a promising therapeutic approach.
5. Conclusions
This study investigates the use of BM-MNCs for the
treatment of chronic patellar tendinopathy. Patients showed
statistically clinical improvement at 5-year followup. Inoc-
ulation of BM-MNCs could be considered as a potential
therapy for those patients with chronic patellar tendinopathy
refractory to nonoperative treatments.
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